Tuesday, December 9, 2026
| Product Theater | Description and Speakers | Time and Location |
|---|---|---|
| Pfizer Discover What’s Possible in HER2+ Metastatic Breast Cancer: Pfizer’s Commitment to Patients and Innovation | Please join us for an informative, expert-led Product Theater presented by Daiichi Sankyo, Inc. and AstraZeneca to see the latest clinical data for HER2+ Breast Cancer. Please visit us at Daiichi Sankyo booth #343 and AstraZeneca booth #624. Speakers: VK Gadi David Page | Time: 12:30 p.m. Location: Theater A |
Daiichi Sankyo The Latest Treatment Approaches Across Disease Settings for HER2+ Breast Cancer | Product theater details to come. Speakers: Linnea I. Chap, MD — Director of Breast Cancer and Women’s Oncology, Beverly Hills Cancer Center Michael F. Press, MD, PhD — Professor of Pathology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center | Time: 12:30 p.m. Location: Theater |
| GE Healthcare | Product theater details to come. | Time: 2:30 p.m. Location: Theater A |
| Merk Select Treatment Options for Appropriate Patients With Certain Types of TNBC | Product theater details to come. Speakers: Fadi Braiteh, M.D. | Time: 2:30 p.m. Location: Theater B |
| Rigel An Overview of VEPPANU (vedepgestrant) for 2L+ Treatment of ESR1m ER+/HER2- mBC | Product theater details to come. Speaker(s): Anish Konde, MD — Providence Health in Seattle | Time: 4:30 p.m. Location: Theater A |
| AstraZeneca-Cami A Next-Generation 1L Approach in HR+/HER2− mBC: The Role of E | Product theater details to come. Speakers: Phillip Lammers, MD — Chief of Medical Oncology and Medical Director of Oncology Clinical Research, Baptist Cancer Center, Memphis, TN | Time: 4:30 p.m. Location: Theater B |
Wednesday, December 10, 2026
| Company | Product Theater Title and Speakers | Time and Location |
|---|---|---|
| Eli Lilly Interrupt progression: Using an oral ER antagonist and CDK4/6 inhibitor combination for appropriate patients | Description: Join us to learn more about Inluriyo® (imlunestrant) + Verzenio® (abemaciclib). This program is sponsored by Lilly USA, LLC. Speaker(s): Anne O’Dea | Time: 12:30 p.m. Location: Theater A |
| Novartis Navigating the HR+/HER2- Breast Cancer Landscape: Insights for Clinical Practice | Speaker(s): Dr. Ursa Brown-Glaberman — Christus St. Vincent Regional Cancer Center, Santa Fe, NM | Time: 12:30 p.m. Location: Theater B |
| Bio-Rad Highly Sensitive and Cost-Effective ESR1 Mutation Detection for Breast Cancer Research Applications | Description: This workshop will examine ESR1 mutation analysis in hormone receptor-positive breast cancer research, with a focus on liquid biopsy workflows and Droplet Digital PCR (ddPCR) technology. Translational research and precision oncology experts will discuss ddPCR-based assay setup, operational efficiency, reporting practices, and analytical performance considerations, including sensitivity, turnaround time, workflow simplicity, and cost. The session will also review published and emerging evidence comparing ddPCR with other molecular testing approaches and highlight practical considerations for studying longitudinal molecular changes while supporting efficient laboratory operations. Speaker(s): Isaac Garcia-Murillas, PhD — The Institute of Cancer Research & The Royal Marsden Hospital, London, England; Gary Pestano, PhD — Biodesix, Inc., Louisville, CO; Prithwish Pal, PhD — Bio-Rad Laboratories, Pleasanton, CA | Time: 2:30 p.m. Location: Theater A |
| Hologic A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i | Product theater details to come. | Time: 2:30 p.m. Location: Theater B |
| Exact Sciences The Trusted Leader in Breast Cancer Insights. Expanded. The Emerging Role of MRD and ctDNA Surveillance in HR+/HER2- Early Breast Cancer | Description: Despite effective adjuvant therapy, some patients with early breast cancer remain at risk for late recurrence that imaging and clinicopathologic assessment alone may not detect. This Product Theater examines the emerging role of molecular residual disease (MRD) and circulating tumor DNA (ctDNA) surveillance across the breast cancer continuum. Faculty will review the science behind next-generation, tumor-informed whole-genome sequencing; evolving clinical evidence in breast cancer; and practical considerations for integrating serial ctDNA monitoring into follow-up care, including how MRD insights may complement established genomic risk assessment to inform individualized, longitudinal patient management. Speaker(s): Rick Baehner, MD — Abbott Cancer Diagnostics; Christy A. Russell, MD — Abbott Cancer Diagnostics | Time: 4:30 p.m. Location: Theater A |
| AstraZeneca-Truqap A 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA, AKT1, or PTEN Alterations Following Progression on or After ET ± CDK4/6i | Product theater details to come. | Time: 4:30 p.m. Location: Theater B |